T. Mikkelsen

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan

Richard Zuniga, Roy Torcuator, Rajan Jain et al. · Journal of Neuro-Oncology · 2008 · 273 citations

Neuro-oncology, Medicine, Cancer Management +8

A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM)

Timothy F. Cloughesy, Michael D. Prados, Patrick Y. Wen et al. · Journal of Clinical Oncology · 2008 · 145 citations

Neuro-oncology, Phase Ii, Medicine +14

A safety run‐in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)

Burt Nabors, T. Mikkelsen, Monika E. Hegi et al. · Cancer · 2012 · 124 citations · Full text

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab

J.S. Wefel, Timothy F. Cloughesy, James L. Zazzali et al. · Neuro-Oncology · 2011 · 104 citations · Full text

Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB).

Patrick Y. Wen, Michael D. Prados, D. Schiff et al. · Journal of Clinical Oncology · 2010 · 65 citations

Pathology, Phase Ii Study, Prior Aat +17